Escitalopram

Lexapro | Cipralex

FDA ApprovedCentral Nervous System AgentsSSRI Antidepressants
FDA: 2002Half-life: 27-32 hoursPregnancy: Category C

Overview

Selective serotonin reuptake inhibitor (SSRI). Potently and selectively inhibits neuronal reuptake of serotonin (5-HT), enhancing serotonergic neurotransmission.

Indications

  • Major depressive disorder (MDD)
  • Generalized anxiety disorder (GAD)
  • Social anxiety disorder (off-label)
  • Obsessive-compulsive disorder (off-label)
  • Panic disorder (off-label)

Contraindications

  • Use of MAOIs within 14 days
  • Concurrent use with pimozide
  • Hypersensitivity to escitalopram or citalopram

Classification

Mechanism of Action

Selective serotonin reuptake inhibitor (SSRI). Potently and selectively inhibits neuronal reuptake of serotonin (5-HT), enhancing serotonergic neurotransmission.

Pharmacodynamics

S-enantiomer of citalopram and the most selective SSRI available. Minimal effects on norepinephrine and dopamine reuptake. Low affinity for histaminic, muscarinic, and adrenergic receptors.

Pharmacokinetics

Absorption
Rapidly absorbed. Not affected by food.
Distribution
Volume of distribution ~12 L/kg.
Metabolism
Hepatic via CYP3A4 and CYP2C19 to demethylated and didemethylated metabolites (less active).
Excretion
Renal (8% unchanged) and fecal.
Half-life
27-32 hours
Bioavailability
80%
Protein Binding
56%

Dosage

Typical dosage: 10-20mg once daily

Available Forms

  • Tablet
  • Oral solution

Side Effects

Common

  • Nausea
  • Insomnia
  • Ejaculation disorder
  • Somnolence
  • Increased sweating
  • Fatigue

Serious

  • Serotonin syndrome
  • QT prolongation
  • Suicidal thoughts (age <25)
  • Hyponatremia/SIADH

Rare

  • Angle-closure glaucoma
  • Bleeding events
  • Seizures

Drug Interactions

major

Risk of serotonin syndrome — potentially fatal. Wait at least 14 days between MAOI discontinuation and escitalopram initiation.

major

Increased risk of serotonin syndrome and seizures. Use with caution and monitor closely.

Warnings

⚠️BLACK BOX WARNING

Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years) in short-term studies. Monitor closely for clinical worsening and emergence of suicidal thoughts.

Pregnancy

Category C

Toxicity

Not established in humans

Overdose

Symptoms: nausea, vomiting, tremor, drowsiness, tachycardia, seizures, QT prolongation. Treatment: activated charcoal, supportive care, cardiac monitoring.

References

Looking for patient-friendly information? Visit RemedyDoor for easy-to-read guides about this medication.